Highbridge Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Highbridge Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-110,000	Closed	-$4.23M	–	449
2023 Q2	$4.23M	Buy	+110,000	New	+$2.82M	0.19%	82
2017 Q3	–	Sell	-5,154	Closed	-$294K	–	1841
2017 Q2	$294K	Sell	5,154 -10,713	-68%	-$538K	﹤0.01%	972
2017 Q1	$853K	Buy	+15,867	New	+$896K	0.01%	674

Highbridge Capital Management's KDNY Position: Q3 2023 in Review

Highbridge Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 110,000 shares — an estimated $4.23M sold.

Highbridge Capital Management first reported a position in KDNY in Q1 2017 and held it in 3 quarters. The position peaked at $4.23M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Highbridge Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Highbridge Capital Management sold 110,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.23M.
Highbridge Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
Highbridge Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.23M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Highbridge Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.